Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva®, enhanced by olodaterol Spiolto® Respimat® provides significant improvements in lung function, COPD symptoms, quality of ...
Ingelheim, Germany, 3rd September, 2012 – New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...
RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...
SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiolto Respimat contains the active ingredients tiotropium (as ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiriva Respimat contains the active ingredient tiotropium. Spiriva ...
Boehringer Ingelheim is celebrating after the US Food and Drug Administration approved the mist version of its chronic obstructive pulmonary disease blockbuster Spiriva. Boehringer Ingelheim is ...
Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim (Photo: Business Wire) Boehringer Ingelheim today announced submission of applications to extend the indication for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback